HCPLive Network

Phase III Study Results for Levomilnacipran Promising

Forest Laboratories and Pierre Fabre Medicament made an announcement today stating that the main goal of their phase three study for levomilnacipran, a possible future treatment of major depressive disorder (MDD), had been achieved.

These recent findings are a relief for the two developmental partners as well as the medical community, especially since a previous phase three study earlier this year of levomilnacipran failed to exhibit optimistic results; the findings of that study showed that the drug decreased depression no more effectively than a placebo.

The purpose of this double-blind, randomized, placebo-controlled study was to test the drug's efficacy, safety, and tolerability.

The eight-week trial focused on 720 patients, whose depression was measured by the six-point Montgomery-Asberg Depression Rating Scale (MADRS). The researchers found that levomilnacipran decreased the depression of the participants, and further, they discovered that the participant’s scores lowered as doses increased.

MDD is estimated to affect roughly fifteen-million people in the United States each year.

"Depressed patients often struggle to find the right antidepressant and the need for new medications is high," said Dr. Marco Taglietti, Forest president and senior vice president of research and development.

The drug works through inhibiting the re-uptake of norepinephrine and serotonin, which increases the levels of these two neurotransmitters that are known to affect mood.

"These positive Phase III results are very encouraging and support the continued research of levomilnacipran in adult patients with major depressive disorder," concluded Taglietti.
 

Further Reading
Study results show that patients diagnosed with fibromyalgia often discontinue treatment. Those that do not frequently augment their initial treatment regimen with one or more additional medications, including some that are not recommended by current guidelines.
The patient-reported painDETECT questionnaire has been shown to accurately and reliably identify neuropathic pain across a range of conditions.
Knowledge of dietary supplement properties, uses, and contraindications is highly relevant to any health care practitioner that treats patients with chronic pain. Data shows that the top four reasons for supplement use are back pain, neck pain, joint pain, and arthritis.
Research indicates that there are probable etiologies of low back pain that can affect treatment outcome and that ignoring pain can possibly cause chronic neurological changes.
Researchers are learning more about the ways in which gut microbiota interact with the central nervous system and the role this can play in pain management.
Although the underlying mechanisms are not fully understood, opioid-induced hyperalgesia occurs in some patients on higher doses of opioids. Treatment options include reducing, rotating, or completely tapering the opioid regimen.
Magnetic resonance is an effective alternative to biopsy for identifying and quantifying fats in the liver, according to results from a study led by a research team at the University of the Basque Country.
More Reading